Please assess the completion status of the following clinical trial:

Trial Title: Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing diagnostic upper endoscopy in our endoscopic room were enrolled.~Exclusion Criteria:~* A therapeutic upper endoscopic procedure, sedated endoscopy, contraindication to Buscopan (hyoscine N-butylbromide)~* Allergy to meperidine~* American Society of Anesthesiology (ASA) risk Class 3 or higher~* Renal failure~* Decompensated cirrhosis~* Aged less than 20 years or more than 65 years~* Pregnancy~* Refusal to provide written informed consent.

- Gender: None
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- meperidine (Type: EXPERIMENTAL): 25 mg of meperidine is injected intramuscularly before EGD
- placebo (Type: PLACEBO_COMPARATOR): placebo was given intramuscularly before EGD

Based on this trial design, predict the completion outcome and termination type (if applicable).